A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00547469|
Recruitment Status : Unknown
Verified April 2008 by Dynogen Pharmaceuticals.
Recruitment status was: Recruiting
First Posted : October 22, 2007
Last Update Posted : April 8, 2008
|Condition or disease||Intervention/treatment||Phase|
|Irritable Bowel Syndrome||Drug: DDP733||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||360 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of DDP733 in Female Patients With Irritable Bowel Syndrome With Constipation|
|Study Start Date :||October 2007|
- Overall Subject Global Assessment (SGA) of relief of IBS symptoms, collected weekly
- Weekly assessments of abdominal discomfort/pain, bowel habit, and satisfaction with bowel habit.
- Other secondary efficacy variables reflecting IBS symptoms include daily assessments of abdominal discomfort/pain; abdominal bloating, the number and consistency of stools, straining at defecation, and feeling of incomplete evacuation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00547469
|Study Director:||Dynogen Study Director, MD||Dynogen Pharmaceuticals, Inc|